Reneuron Share News (RENE)

LONDON (Dow Jones)--ReNeuron Group PLC (RENE.LN) said Tuesday that for the year ended March 31, it made a pretax loss of GBP6.2 million on revenue of GBP31,000. MAIN FACTS: -Revenue GBP31,000 (2009: GBP93,000) -Operating loss GBP6.2 million (2009: loss GBP4.7 million) -Pretax loss GBP6.2 million (2009: loss GBP4.7 million) -Loss before exceptional items and tax credit reduced to GBP3.9 million (2009: GBP4.7 million). -Loss for the year increased to GBP5.9 million (2009: GBP3.7 million), after GBP2.3 million non-recurring, non-cash exceptional charges relating to write-down of non-core intangible and tangible assets -Loss per share 1.8 pence (2009: loss 2.4 pence) -Net cash outflow from operating activities reduced to GBP2.6 million (2009: GBP4.4 million), reflecting leaner, tightly-controlled underlying cost base -Cash and cash equivalents at March 31 of GBP5.5 million (2009: GBP0.9 million), with further GBP4.9 million available from equity finance facility -Intends to continue dialogue with regulatory authorities in a number of key territories regarding initial clinical trials with ReN009. -Cautiously expects to be in a position to commence clinical trials of ReN009 in early 2012. -Shares closed Monday at 4.9 pence. -By Iain Packham, Dow Jones Newswires; 44-20-7842-9269; iain.packham@dowjones.com (END) Dow Jones Newswires June 29, 2010 02:51 ET (06:51 GMT)